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BACKGROUND: The aim of this study was to investigate the expression of toll-like receptor 2 (TLR2) on cells associated with oral
squamous cell carcinoma, epithelial dysplasia and irritative hyperplasia, using immunohistochemistry.
RESULTS: More immune cells expressed TLR2 in carcinoma and dysplasia than in hyperplasia (Po0.001). No hyperplastic samples
showed positive TLR2 staining on keratinocytes, whereas keratinocytes in 64% of cases of carcinoma and 74% of cases of dysplasia
were TLR2 positive.
CONCLUSION: Positive TLR2 expression in the microenvironment suggests activation of immune surveillance against the altered
epithelium, whereas TLR2 expression by malignant keratinocytes may be indicative of resistance to apoptosis as a pro-survival
mechanism.
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The connective tissue adjacent to oral squamous cell carcinoma
(OSCC), epithelial dysplasia (ED) and in irritative hyperplasia (IH)
is infiltrated by chronic inflammatory cells (CIC) and may exhibit
increased vascularity with numerous endothelial cell (EC)-lined
vessels. The CIC and EC communicate with other cells in the
vicinity through inflammatory mediators and receptors such
as toll-like receptors (TLRs). Toll-like receptor 2 is a type I
transmembrane protein, which recognises a wide variety of
pathogen-associated molecular patterns (PAMPs) from exogenous
pathogens, as well as endogenous damage-associated molecular
patterns (DAMPs) including heat shock proteins and high-
mobility group box 1 protein (HMGB1) (Sato et al, 2009).
Toll-like receptors share a common signalling pathway through
myeloid differentiation protein 88, nuclear factor k-light-chain
enhancer of activated B cells (NF-kB) and mitogen-associated
protein kinase, eventually leading to the production of type 1
interferon and an immune regulatory response (Akira and Takeda,
2004; Kumagai et al, 2008). Toll-like receptor expression induces
reactive oxygen species and nitrogen intermediates, activates the
cytokine network, initiates signal transduction cascades, increases
phagocytic efficacy, is associated with maturation of dendritic cells
and activates apoptotic pathways (Akira et al, 2001; Liu, 2006;
Wang et al, 2008).
Research relating to TLRs has concentrated primarily on
immune cells, but they are also expressed on normal and
chronically inflamed epithelial cells of skin and mucosal surfaces
(Sato et al, 2009). Further, some epithelial tumour cells have been
shown to express TLRs and this may confer advantage to the
tumour cell (Szczepanski et al, 2007, 2009; Sato et al, 2009).
In this study, we investigated TLR2 expression by keratinocytes
and other cells in the microenvironment of human OSCC, ED
and IH.
MATERIALS AND METHODS
Samples were selected from archival formalin fixed paraffin-
embedded tissues accessioned in the Medlab Dental Oral
Pathology Diagnostic Service, Faculty of Dentistry, University of
Otago. Histological reports were reviewed and tissues from 50
cases of OSCC, 50 white lesions with histological evidence of
epithelial dysplasia and 50 oral mucosal hyperplastic lesions were
obtained. Human fibrous epulis and tonsillar tissues were used as
negative and positive controls.
Immunohistochemical staining was performed using a mono-
clonal mouse antibody against TLR2.1 (sc-21759, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and mouse avidin–biotin
complex (sc-2017, Santa Cruz Biotechnology) with a dilution of
1:50. The sections were processed manually in the routine manner
after being heated with sodium citrate 2.94gl
 1 at 901C for 10min
for antigen retrieval. A sample known to be positive for TLR2 was
included in each run, as was a negative control where the primary
antibody was replaced by isotype-matched mouse IgG1 (Santa
Cruz Biotechnology, cat: 2025, at 1mgml
 1 recommended dilution)
(Figure 1A). All samples were counterstained with haematoxylin.
The slides were assessed blind with light microscopy (Olympus
BX50; Olympus Corp., Tokyo, Japan), by one of the authors (LKN)
who had been trained and calibrated by a specialist oral
pathologist (AMR). CIC and EC with dark brown nuclear and
cytoplasmic staining visualised at  200 magnification were
classified as being TLR2 positive. Those with pale or no staining
were considered negative. Toll-like receptor 2 expression by
keratinocytes was categorised into negative, weakly positive (pale
brown cytoplasmic staining) or strongly positive (dark brown
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scytoplasmic staining). Where there was doubt about the intensity
of the staining, reference was made to photographs that had been
prepared as standards. A standardised methodical microscopic
evaluation of the tissue was carried out beginning at one edge of
the slide and assessing every second high power field, outlined by a
1cm square 10 10 eyepiece graticule. Examination continued
until 1000 CIC and EC in the sub-epithelial connective tissue (IH
and ED) and in the connective tissue adjacent to invading
epithelial islands (OSCC) were counted. The number of these cells
showing positive TLR2 expression was recorded and expressed as a
percentage. Toll-like receptor 2 expression by 1000 keratinocytes,
in epithelium delineated in the graticule adjacent to the connective
tissue, was analysed and the cells were categorised as being
negative, weakly positive or strongly positive, as we have
previously reported for assessment of other antibodies in oral
epithelium (Kerdpon et al, 1997). The reproducibility of this
method was confirmed by all the slides being re-analysed by the
first author 4 weeks after the completion of the main assessment
and by a selection of slides being counted by another specialist oral
pathologist (HMH).
Inter-observer correlation was calculated using Pearson’s
correlation coefficient. Statistical analyses of the experimental
data was performed using Mann–Whitney’s U-test. A comparison
of TLR2 expression between all three tissues and correlation
with variables was made using one-way ANOVA and t-test.
A probability value below 0.05 was considered statistically
significant.
RESULTS
More CIC and EC in the connective tissue of OSCC (19.9%) and ED
(16.4%) expressed TLR2 by comparison with those associated with
IH (7.5%) (Table 1 and Figure 1). The data were found not to be
normally distributed, hence, the mean percentage for each type of
tissue was calculated as mean rank (Table 1). Comparisons of
mean TLR2 expression in the microenvironment were calculated
using the Mann–Whitney’s U-test in order to confirm any
statistical differences. t-tests and one-way ANOVA confirmed that
TLR2 expression in the microenvironment was not affected by
patient age, patient gender, site, histological differentiation or by
TLR2 expression on lesional keratinocytes. The keratinocytes in IH
did not express TLR2 (Figure 1). In contrast, keratinocytes in 64%
of OSCC showed weak or strong TLR2 expression, as did 74% of
ED (Table 2, Figure 1).
Figure 1 Photomicrographs of OSCC isotype control (A) and irritative hyperplasia (B) demonstrating no TLR 2 expression in the epithelium or on
inflammatory cells in the connective tissue. The invading epithelial islands of an OSCC demonstrate weakly (C) and strongly (D) positive-TLR 2 expression.
Some inflammatory cells in the adjacent fibrous connective tissue show strong positivity in both (C) and (D).
Table 1 Comparison of TLR2 expression in OSCC, ED and IH
Lesion TLR2 mean (%) TLR2 mean rank
OSCC 19.9 93.7
ED 16.4 80.8
IH 7.5 46.5
Abbreviations: ED¼epithelial dysplasia; IH¼irritative hyperplasia; OSCC¼oral
squamous cell carcinoma; TLR2¼tumour like receptor 2. OSCC vs IH, Po0.001
(Mann–Whitney’s U-test). ED vs IH, Po0.001 (Mann–Whitney’s U-test). OSCC vs
ED, P40.05 (Mann–Whitney’s U-test).
Table 2 Expression of TLR2 by keratinocytes in OSCC, ED and IH
Lesion
Negative
(%)
Weakly
positive (%)
Strongly
positive (%)
OSCC 36 26 38
ED 26 44 30
IH 100 — —
Abbreviations: ED¼epithelial dysplasia; IH¼irritative hyperplasia; OSCC¼oral
squamous cell carcinoma.
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showing significant agreement between the two observers.
DISCUSSION
This study clearly demonstrated higher TLR2 expression on cells
in the microenvironment of OSCC and dysplasia as compared with
hyperplasia. Toll-like receptor expression on inflammatory cells
adjacent to tumour cells has been previously described and has
been considered to be beneficial to the host by enhancing
maturation of antigen-presenting cells and inhibiting tumour
growth (Apetoh et al, 2007; Szczepanski et al, 2009). We suggest
that another possible mechanism that may contribute to tumour
suppression is TLR-induced apoptosis of the altered epithelial
cells. The keratinocytes in OSCC and ED have undergone genetic
mutations leading to alterations to protein products and/or
alterations to chromosome structure (Califano et al, 1996; Tsui
et al, 2008; Sheu et al, 2009) and could be perceived as ‘foreign’ by
the immune system. This might result in high TLR2 expression by
the CIC and EC in the vicinity, as found in this study, and lead to
TLR-induced apoptosis in these altered tissues (Huang et al, 2005,
2007; Chen et al, 2007). Conversely, DAMPS released from injured
or necrotic keratinocytes may be recognised by TLRs on immune
cells in the microenvironment leading to signals that disrupt the
anti-tumour response leading to cancer progression (Lotze et al,
2007). The DAMP, HMGB1, has been found to be upregulated
in some carcinomas in which it activates TLRs, including TLR2,
on immune cells and enhances tumour progression (Ellerman
et al, 2007).
This study found that 64% of malignant keratinocytes in OSCC
and 74% of dysplastic keratinocytes in ED expressed TLR2, but
that TLR2 was not expressed on the keratinocytes in the
epithelium, which was hyperplastic in response to chronic
irritation. To our knowledge, this is the first report demonstrating
TLR2 expression on human oral cancer cells and dysplastic oral
epithelial cells. Cancer cells from other sites (e.g., melanoma,
breast) have been shown to express TLR2, and TLR4 expression has
been noted on tumour cells in head and neck squamous cell
carcinoma (Goto et al, 2008; Szczepanski et al, 2009; Xie et al,
2009). The expression of TLR2 on malignant keratinocytes suggests
that they may be apoptotic resistant, as well as being able to induce
apoptosis in targeted immune cells in the vicinity (Chen et al, 2007;
Conroy et al, 2008; Huang et al, 2008). These cancer cells appear to
have the ability to control the tumour microenvironment to their
advantage and influence the immune cells present (Huang et al,
2005; He et al, 2007; Chen et al, 2008), hence, creating a pro-tumour
outcome as proposed by Killeen et al (2006).
In conclusion, this study showed that TLR2 was expressed on
the keratinocytes of dysplastic epithelium and OSCC. Positive
TLR2 expression in the microenvironment suggests that immune
surveillance is activated against the altered cells, whereas TLR2
expression by malignant keratinocytes may correlate with
apoptosis resistance and, hence, the survival of tumour cells.
Now that TLR2-positive cells have been detected in OSCC, this
proposition needs to be tested to determine their functional
activity in terms of gene expression and cytokine profiling.
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